Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cipros 20 association in dyslipidemia
NCT03540355Phase 3Completed
- Sponsor
- EMS
- Start
- Mar 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Cipros 20 association in dyslipidemia (2 arms), sponsored by EMS. Primary endpoints: Reduction of serum triglyceride levels at 12 weeks and Reduction of serum LDL-C at 12 weeks. Started Mar 2021; status: completed.
02
Drugs
Cipros 20 association
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03540355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540355.